Skip to content

Aura Biosciences, Inc. AURA Proceeds From Warrant Exercises

Proceeds From Warrant Exercises at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$53.54M
Immunome logo
ImmunomeIMNM
$0
Summit Therapeutics logo
Summit TherapeuticsSMMT
$0-100%

Other financials

Income statement

See full
Operating income-$34.9M-20.1%
Net income-$33.7M-22.6%
EPS (diluted)-$0.50+9.1%

Balance sheet

See full
Cash & equivalents$84.8M+122%
Total debt$17.0M-7.9%
Total equity$107.2M-16.2%
Total assets$137.7M-11.4%

Cash flow

See full
Operating cash flow-$29.9M-28.0%
CapEx$102.0K-45.5%
Free cash flow-$30.0M-27.4%

Valuation

See full
Market cap$709.23M+89.4%
Enterprise value$641.43M+80.8%

Returns & leverage

See full
Return on equity-95.6%+222pp
Debt / equity0.2×0.0×
Current ratio7.1×-4.0×

Where this comes from

Reported directly by Aura Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromWarrantExercises.

The official record: Aura Biosciences, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aura Biosciences, Inc.'s proceeds from warrant exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aura Biosciences, Inc.'s proceeds from warrant exercises?
Aura Biosciences, Inc. (AURA) reported proceeds from warrant exercises of $123K in Q1 2026.